Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2019 December;110(6) > Minerva Medica 2019 December;110(6):490-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Minerva Medica 2019 December;110(6):490-8

DOI: 10.23736/S0026-4806.19.06046-4

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Benign pancreatic hyperenzymemia-Gullo’s syndrome: focus on this clinical challenge. A monocentric retrospective study

Roberto CATANZARO 1, 2 , Morena SCIUTO 1, 2, Giuseppe ADAMO 1, 2, Martina GUARRERA 3, Francesco MAROTTA 4

1 Section of Gastroenterology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 2 Vittorio Emanuele Policlinic Hospital, Gaspare Rodolico University Hospital, Catania, Italy; 3 Paolo Giaccone University Hospital, Palermo, Italy; 4 ReGenera R&D International for Aging Intervention & San Babila Clinic, Milan, Italy



BACKGROUND: An abnormal and chronic rise of pancreatic enzymes in the blood is most often due to pancreatic diseases, primarily inflammatory or neoplastic, or to numerous extra-pancreatic pathologies. Benign chronic pancreatic hyperenzymemia was described for the first time - as a separate nosological entity - in 1996 by Lucio Gullo et al. They demonstrated the existence of a benign chronic pancreatic hyperenzymemia in asymptomatic subjects and without clinical implications; however, a follow-up of at least 1-2 years is necessary during which no specific symptomatology or morpho-functional impairment of the pancreas should occur, also evaluated through the aid of instrumental diagnostic investigations such as ultrasonography (US), computed tomography (CT) or magnetic resonance cholangio pancreatography (MRCP).
METHODS: This study was performed with the analysis of a group of 43 subjects arrived at the observation of the Gastroenterology Team of Policlinico Hospital G. Rodolico in Catania-Italy which presented a chronic pancreatic hyperenzymemia, in order to establish the actual benignity of this condition over time.
RESULTS: During the follow-up, pancreatic alterations and hyperenzymemia were found in 10 patients, while hyperenzymemia was not associated with pancreatic modification in 33 patients.
CONCLUSIONS: Because of this enzymatic elevation - often conspicuous and lasting - the patient is often particularly anxious. For the same reason, the patient frequently undergoes very expensive laboratory and instrumental diagnostic methods. Good knowledge of the syndrome makes it possible to manage the event more rationally, also to reduce management costs to a minimum.


KEY WORDS: Pancreatic diseases; Hyperlipasemia; Diagnosis

top of page